Compare Msci Inc (MSCI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Revvity Inc — how do they compare? Msci Inc trades at $565.12 (market cap $40.38B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Msci Inc is far larger — about 2.4× Revvity Inc's market cap, and Msci Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Revvity Inc for 12 Days on average.
| MSCI | RVTY | |
|---|---|---|
Market Cap | $40.38B | $16.98B |
Volume | 414,140 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $643.83 | $157.36 |
52-Week Low | $511.84 | $82.26 |
Typical Hold Time | 82 Days | 12 Days |
Enterprise Value | $46.54B | $19.30B |
Dividend Yield | 1.48% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $561.67, up 1.13% in 24 hours, with a bullish technical signal and strong fundamental performance. The stock has exceeded earnings expectations in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by high profit margins and recurring subscription income. Recent news highlights the completion of the First Street acquisition and upcoming earnings call, reinforcing positive business momentum.
The outlook for MSCI remains favorable, driven by robust earnings, analyst consensus of a buy rating, and a price target implying significant upside. Key risks include high valuation multiples and market sensitivity to financial services demand. Investors should weigh strong profitability against potential volatility from economic cycles.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
